Stocks · News reference
HCW Biologics Restates Q1 2026 EPS $1.39, Sales $6.543M Up From $5.065K YoY
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — HCW Biologics Inc. (HCWB)
Filed: 2026-09-24 AccNo: 0001493152-26-044078 Size: 1 MB Item 1.01: Entry into a Material Definitive Agreement Item 3.02: Unregistered Sales of Equity Securities Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
HCW Biologics Prices $1.5M Private Placement Of 903,614 Units At $1.6599 Per Unit
Company agreed to issue and sell an aggregate of 903,614 units (the "Units"), with each Unit consisting of (i) one pre-funded warrant (a "Pre-Funded Warrant") to purchase one share of the Company’s
HCW Biologics Entered an Exclusive Distribution Agreement with Akron Biotech to Commercialize HCW11-006 as Reagent Used to Support Production of Highly Functional Human CAR-T Cells
HCW Biologics Inc. announced an exclusive distribution agreement with Akron Biotech to commercialize HCW11-006, a multi-cytokine fusion molecule designed to improve CAR-T cell manufacturing. The reagent demonstrated superior performance in preclinical studies, generating more potent and longer-lasting CAR-T cells while potentially reducing production costs compared to conventional methods.